Zentalis Pharmaceuticals, Inc. Common Stock ZNTL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:21:53.289Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:59:31.760934865Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T03:21:42.454152+00:00
Zentalis Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.47 | 467.1% | 61.9% | |||
| 25Δ | 2.67 | 440.2% | 56.9% | |||
| 30Δ | 2.87 | 417.5% | 52.4% | |||
| 35Δ | 9.78 | 352.8% | 444.7% | 3.06 | 394.8% | 47.8% |
| 40Δ | 9.43 | 378.5% | 430.9% | 3.25 | 372.1% | 43.2% |
| 45Δ | 9.08 | 404.2% | 417.1% | 3.45 | 349.4% | 38.7% |
| 50Δ | 8.74 | 429.9% | 403.3% | 3.64 | 326.6% | 34.1% |
| 55Δ | 8.39 | 455.6% | 389.5% | 3.83 | 303.9% | 29.5% |
| 60Δ | 4.03 | 281.2% | 25.0% | |||
| 65Δ | 4.22 | 258.5% | 20.4% | |||
| 70Δ | 4.41 | 235.8% | 15.8% | |||
| 75Δ | 4.61 | 213.1% | 11.3% | |||
| 80Δ | 4.80 | 190.4% | 6.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.47
- IV
- 467.1%
- B/E move
- 61.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.67
- IV
- 440.2%
- B/E move
- 56.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.87
- IV
- 417.5%
- B/E move
- 52.4%
35Δ
- Pseudo strike
- 9.78
- IV
- 352.8%
- B/E move
- 444.7%
- Pseudo strike
- 3.06
- IV
- 394.8%
- B/E move
- 47.8%
40Δ
- Pseudo strike
- 9.43
- IV
- 378.5%
- B/E move
- 430.9%
- Pseudo strike
- 3.25
- IV
- 372.1%
- B/E move
- 43.2%
45Δ
- Pseudo strike
- 9.08
- IV
- 404.2%
- B/E move
- 417.1%
- Pseudo strike
- 3.45
- IV
- 349.4%
- B/E move
- 38.7%
50Δ
- Pseudo strike
- 8.74
- IV
- 429.9%
- B/E move
- 403.3%
- Pseudo strike
- 3.64
- IV
- 326.6%
- B/E move
- 34.1%
55Δ
- Pseudo strike
- 8.39
- IV
- 455.6%
- B/E move
- 389.5%
- Pseudo strike
- 3.83
- IV
- 303.9%
- B/E move
- 29.5%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.03
- IV
- 281.2%
- B/E move
- 25.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.22
- IV
- 258.5%
- B/E move
- 20.4%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.41
- IV
- 235.8%
- B/E move
- 15.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.61
- IV
- 213.1%
- B/E move
- 11.3%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.80
- IV
- 190.4%
- B/E move
- 6.7%
Options history
No recorded observations
Biotechnology
ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →